Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
Shomali W, Colucci P, George TI, Kiladjian JJ, Langford C, Patel JL, Reiter A, Vannucchi AM, Gotlib J. Shomali W, et al. Among authors: kiladjian jj. Leukemia. 2023 May;37(5):981-987. doi: 10.1038/s41375-023-01859-3. Epub 2023 Apr 19. Leukemia. 2023. PMID: 37076693 Free PMC article. Review. No abstract available.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Among authors: kiladjian jj. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Incidence of blast phase in myelofibrosis according to anemia severity.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian JJ, Elli EM, Polverelli N, Gotlib J, Albano F, Silver RT, Benevolo G, Ross DM, Devos T, Borsani O, Barbui T, Porta MGD, Bertù L, Komrokji R, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: kiladjian jj. EJHaem. 2023 Jul 17;4(3):679-689. doi: 10.1002/jha2.745. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601878 Free PMC article.
Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO. Verstovsek S, et al. Among authors: kiladjian jj. Haematologica. 2024 Apr 1;109(4):3010. doi: 10.3324/haematol.2023.284815. Haematologica. 2024. PMID: 38562076 Free PMC article. No abstract available.
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison C, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kroger N, Kuykendall AT, Loscocco GG, Mascarenhas J, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani A, Patel A, Pemmaraju N, Rambaldi A, Rampal R, Sirhan S, Szuber N, Talpaz M, Vachhani PJ, Vannucchi AM, Barbui T. Tefferi A, et al. Among authors: kiladjian jj. Blood. 2024 Oct 24;144(17):1813-1820. doi: 10.1182/blood.2024025802. Blood. 2024. PMID: 39116296
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: kiladjian jj. Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634011 Free PMC article. No abstract available.
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group.
Koschmieder S, Bose P, Ellis MH, Gupta V, Kiladjian JJ, Mascarenhas J, Mathews V, Passamonti F, Harrison C. Koschmieder S, et al. Among authors: kiladjian jj. Leukemia. 2024 Aug;38(8):1831-1838. doi: 10.1038/s41375-024-02330-7. Epub 2024 Jul 9. Leukemia. 2024. PMID: 38982261 Free PMC article. No abstract available.
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H; PROUD-PV Study Group. Kiladjian JJ, et al. Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24. Leukemia. 2022. PMID: 35210530 Free PMC article. No abstract available.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. Janku F, et al. Among authors: kiladjian jj. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039779 Clinical Trial.
293 results